"Dermatitis, Atopic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.
| Descriptor ID |
D003876
|
| MeSH Number(s) |
C16.320.850.210 C17.800.174.193 C17.800.815.193 C17.800.827.210 C20.543.480.343
|
| Concept/Terms |
Dermatitis, Atopic- Dermatitis, Atopic
- Atopic Dermatitides
- Atopic Dermatitis
- Dermatitides, Atopic
- Neurodermatitis, Atopic
- Atopic Neurodermatitides
- Atopic Neurodermatitis
- Neurodermatitides, Atopic
- Neurodermatitis, Disseminated
- Disseminated Neurodermatitides
- Disseminated Neurodermatitis
- Neurodermatitides, Disseminated
- Eczema, Atopic
- Atopic Eczema
|
Below are MeSH descriptors whose meaning is more general than "Dermatitis, Atopic".
- Diseases [C]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Skin Diseases, Genetic [C16.320.850]
- Dermatitis, Atopic [C16.320.850.210]
- Skin and Connective Tissue Diseases [C17]
- Skin Diseases [C17.800]
- Dermatitis [C17.800.174]
- Dermatitis, Atopic [C17.800.174.193]
- Skin Diseases, Eczematous [C17.800.815]
- Dermatitis, Atopic [C17.800.815.193]
- Skin Diseases, Genetic [C17.800.827]
- Dermatitis, Atopic [C17.800.827.210]
- Immune System Diseases [C20]
- Hypersensitivity [C20.543]
- Hypersensitivity, Immediate [C20.543.480]
- Dermatitis, Atopic [C20.543.480.343]
Below are MeSH descriptors whose meaning is more specific than "Dermatitis, Atopic".
This graph shows the total number of publications written about "Dermatitis, Atopic" by people in this website by year, and whether "Dermatitis, Atopic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 72 | 6 | 78 |
| 2018 | 81 | 11 | 92 |
| 2019 | 32 | 9 | 41 |
| 2020 | 9 | 1 | 10 |
| 2021 | 12 | 1 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Dermatitis, Atopic" by people in Profiles.
-
The Burden of Coronavirus Disease 2019 and Its Complications in Patients With Atopic Dermatitis-A Nested Case-Control Study. Dermatitis. 2021 Oct 01; 32(1S):S45-S52.
-
Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis. Dermatitis. 2021 Oct 01; 32(1S):S4-S7.
-
Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis. Dermatitis. 2021 Oct 01; 32(1S):e80-e82.
-
Management of allergic diseases in pregnancy. Allergy. 2022 03; 77(3):798-811.
-
Care for children with atopic dermatitis in the Netherlands during the COVID-19 pandemic: Lessons from the first wave and implications for the future. J Dermatol. 2021 Dec; 48(12):1863-1870.
-
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. Clin Exp Dermatol. 2022 01; 47(1):165-167.
-
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep; 22(5):693-707.
-
Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management. Hum Vaccin Immunother. 2021 Oct 03; 17(10):3268-3275.
-
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021 09; 34(5):e15035.
-
SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study. Br J Dermatol. 2021 09; 185(3):640-641.